At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,500 enrolled
Drug / intervention
Rituximab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
HD18 for Advanced Stages in Hodgkins Lymphoma
In Brief
A Phase 3 clinical trial evaluating Rituximab and BEACOPP escalated for Hodgkins Lymphoma. Completed, enrolled 1,500 participants across 1 site.
Detailed Summary
This study is designed to test: 1. in patients with negative positron-emission tomography (PET) after 2 cycles of BEACOPPesc chemotherapy: whether the number of cycles can be reduced without compromising progression free survival (PFS) (2 further cycles vs. 6 further cycles) 2. for patients with positive PET after 2 cycles: whether intensifying BEACOPPesc chemotherapy by adding Rituximab improves PFS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHodgkins Lymphoma
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2007
Enrollment StartMay 2008
Primary CompletionJul 2019
Study CompletionJul 2020
TodayJul 2026
First PostedAug 13, 2007
Enrollment StartMay 1, 2008
Primary CompletionJul 1, 2019
Study CompletionJul 1, 2020
TodayJul 2, 2026
Enrollment to primary: 11.2 yearsPosted 18.9 years ago
Interventions
Rituximabdrug
addition of Rituximab to BEACOPP escalated
BEACOPP escalateddrug
chemotherapy with BEACOPP escalated